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Abstract
Epitranscriptomics is a newly burgeoning field pertaining to the complete delineation 
and elucidation of chemical modifications of nucleotides found within all classes of RNA 
that do not involve a change in the ribonucleotide sequence. More than 140 diverse and 
distinct nucleotide modifications have been identified in RNA, dwarfing the number of 
nucleotide modifications found in DNA. The majority of epitranscriptomic modifications 
have been identified in ribosomal RNA (rRNA), transfer RNA (tRNA), and small nuclear 
RNA (snRNA). However, in total, the knowledge of the occurrence, and specifically the 
function, of RNA modifications remains scarce. Recently, the rapid advancement of 
next‐generation sequencing and mass spectrometry technologies have allowed for the 
identification and functional characterization of nucleotide modifications in both pro-
tein‐coding and non‐coding RNA on a global, transcriptome scale. In this chapter, we 
will introduce the concepts of nucleotide modification, summarize transcriptome‐wide 
RNA modification mapping techniques, highlight recent studies exploring the functions 
of RNA modifications and their association to disease, and finally offer insight into the 
future progression of epitranscriptomics.
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1. Introduction
RNA has been shown to play critical roles in regulating cellular functions. Comparative transcrip-
tomics between mammals has revealed that ∼66% of human genomic DNA is transcribed. 
Remarkably, only ∼2% of the transcriptional production is protein‐coding messenger RNA 
(mRNA), while ∼98% encompasses a wide variety of non‐coding RNA (ncRNA) molecules 
[1, 2]. ncRNAs have been classified functionally as either housekeeping or regulatory. The 
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housekeeping ncRNA genes include ribosomal RNA (rRNA), transfer RNA (tRNA), and 
small nuclear RNA (snRNA), while examples of regulatory ncRNAs are microRNA (miRNA) 
and long non‐coding RNA (lncRNA) [3–5]. The complexity of RNA is further complicated 
by numerous post‐transcriptional modifications which alter the chemical structure of the 
nucleotides without changing the nucleotide sequence. Similar to the field of epigenetics 
which investigates the modifications of DNA and histone proteins, the study of chemical 
modifications of RNA is called epitranscriptomics [6, 7]. More than 140 chemically diverse 
and distinct modified nucleotides have been identified in both mRNA and ncRNA, includ-
ing N6‐methyladenosine (m6A), 5‐methyl cytidine (m5C), pseudouridine (Ѱ), adenosine (A) 
to inosine (I), and N1‐methyladenosine (m1A). These modifications have been identified 
mostly in the housekeeping ncRNAs [3, 4, 8]; however, chemical modifications have also 
been detected in mRNA and the regulatory ncRNAs [9–11]. Unfortunately, the knowledge 
about the occurrence and function of RNA modifications at transcriptome level remains 
scarce. Recently, the interest in RNA modifications and their functions have gained momen-
tum owing mainly to the application of novel modifications to next‐generation sequenc-
ing (NGS) and mass spectrometry technologies, which have allowed transcriptome‐wide 
detection of distinct RNA modifications [12, 13]. Accurate regulation of the transcriptome 
is critical for gene expression and its subsequent control of cellular functions, including 
metabolism, proliferation, differentiation, and development. Thus, alterations in transcrip-
tome regulation can disrupt cellular functions and lead to disease. Accumulating evidence 
has identified and functionally characterized several distinct types of chemical modifica-
tions of RNA nucleotides in both protein‐coding and ncRNAs, further advancing the bur-
geoning field of epitranscriptomics. In this chapter, we will first provide an overview of 
RNA modifications and then synopsize several transcriptome‐wide RNA modification map-
ping techniques such as m6A‐seq, m5C‐seq, pseudouridine‐seq, and NAD captureSeq. Next, 
we will highlight novel insights into the potential functions of RNA modifications and their 
disease relevance as revealed and facilitated by epitranscriptomic profiling. Finally, we will 
offer our perspective on how the field will progress or evolve in the near future.
2. An overview of post‐transcriptional modifications of RNA
The process of mRNA maturation involving 5ʹ‐capping, splicing, and polyadenylation has 
been well studied [14]. However, the more subtle post‐transcriptional modifications of 
epitranscriptomics, also termed RNA‐epigenetics, are now just fully coming to light. The 
post‐transcriptional modifications found in RNA are often called marks because they mark 
a region of RNA that potentially contributes to the regulation of cellular processes, includ-
ing gene expression, protein translation, or RNA stability. Like mRNA maturation, enzymes 
are required to catalyze the reactions, which chemically modify RNA nucleotides. The most 
common post‐transcriptional RNA modification, Ψ, was also the first to be discovered [15]. 
Originally discovered in rRNA and tRNA, Ψ modifications are also present in mRNA [16, 
17]. Site‐specific isomerization of uridine (U) to Ψ (5‐ribosyluracil) is irreversibly catalyzed 
via Ψ synthases. The family of Ψ synthases (PUS) consists of enzymes which can either func-
tion independently or those that require H/ACA ribonucleotide complexes [18]. Compared to 
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U, Ψ contains an extra imino group (>C═NH), which serves as an additional hydrogen bond 
donor, while the carbon‐carbon (C─C) glycosidic bond linking the sugar to the base is more 
stable than the carbon‐nitrogen (C─N) found in U. These two chemical changes confer rigid-
ity to the sugar‐phosphate backbone and enhances local base stacking [19].
The most common internal modification in eukaryotic mRNA is m6A [20]. Unlike Ψ, m6A 
modifications are reversible, suggesting that the modifications are involved in regulatory 
switches. Methyltransferases (METTL3, METTL14, and WTAP), termed writers, catalyze the 
methylation of adenosine [21–23], whereas demethylases (FTO and ALKBH5), termed eras-
ers, remove the methyl group [24, 25]. The m6A marks are recognized by YTH domain pro-
teins, termed readers, which regulate mRNA processing and metabolism [26, 27].
An additional class of nucleotide modifications, termed RNA editing, creates an irreversible 
change in the nucleotide sequence. These modifications include insertions, deletions, and 
base substitutions and occur in all classes of RNA. When they occur in mRNA, the amino 
acid sequence of the protein will be altered relative to the sequence encoded by genomic 
DNA. RNA editing by deamination results in adenosine (A) to inosine (I) and cytosine (C) 
to uridine (U). A‐to‐I editing is an abundant class of RNA modifications found throughout 
metazoans [28]. The conversion of A‐to‐I residues by base deamination results in the synthesis 
of distinct proteins, which creates functional diversity and serves to enhance the response to 
rapid environmental changes [29]. RNA editing by deamination is mediated by two major 
classes of enzymes; the first class is a group of tissue‐specific and context‐dependent adenos-
ine deaminases called ADARs [30–32]. The ADAR enzyme class (adenosine deaminases act-
ing on RNA) catalyzes hydrolytic deamination of A‐to‐I in double‐stranded regions of RNA 
secondary structure [33]. The second class of enzymes, the vertebrate‐specific apolipoprotein 
B mRNA editing catalytic polypeptide‐like (APOBEC) family, promotes C‐to‐U editing by 
cytosine deamination [34]. APOBEC1, the first‐discovered member of the APOBEC family, 
was characterized as the zinc‐dependent cytidine deaminase which catalyzed a C‐to‐U modi-
fication, resulting in an in‐frame stop codon in APOB mRNA [35].
3. NGS‐based RNA modification techniques
The first transcriptome‐wide and NGS‐based approach for mapping m6A modifications dem-
onstrated the feasibility of identifying RNA modifications across the entire transcriptome and 
established the field of epitranscriptomics [6]. The most important aspects of NGS‐based tech-
niques are the ability to map modifications on a global scale at the single nucleotide resolution 
and that the modified nucleotides are analyzed within the context of the surrounding gene 
sequence. These features insure that the nucleotide modifications are accurately assigned to 
the appropriate RNA and not falsely attributed to homologous genes or RNA contaminates 
[6]. Now, several high‐throughput NGS‐based technologies, including RNA‐seq, have been 
established to profile and quantitate RNA modifications (m6A, m6Am, m5C, m1A, A‐to‐I, Ѱ, 
and NAD cap). These RNA‐seq‐based methodologies can be divided into two classes: immu-
noprecipitation‐based and chemical‐based methods. Table 1 lists six representative NGS‐
based detection methods of RNA modifications.
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RNA immunoprecipitation (RIP)‐based methods use an RNA modification‐specific antibody 
or an enzyme‐specific antibody to capture modified RNA followed by RNA‐seq. m6A‐seq [26], 
methylated RIP‐seq (MeRIP‐seq) [36] and m6A‐level, and isoform‐characterization sequenc-
ing (m6A‐LAIC‐seq) [37] combine RNA‐seq with RIP specific for m6A methylation. Figure 1A 
displays a typical m6A‐seq workflow. RIP is performed using an anti‐m6A antibody to enrich 
m6A‐modified RNAs followed by cDNA library preparation and high throughput NGS 
sequencing and finally analysis to identify the occurrence and consensus motif (RRACU) of 
global m6A modifications. A modified RIP approach, called m6A individual‐nucleotide‐reso-
lution by cross‐linking and immunoprecipitation (miCLIP), uses ultraviolet light‐induced 
antibody RNA cross‐linking to induce site‐specific mutations at m6A marks. These mutational 
signatures block reverse transcription and facilitate the detection of m6A marks at single‐
nucleotide resolution [38]. As illustrated in Figure 1B, m1A‐ID‐seq, which combines m1A 
Figure 1. Immunoprecipitation‐based strategies to detect RNA modifications. (A) m6A‐seq workflow: RNA immuno‐
precipitation is done using anti‐m6A antibody to enrich m6A‐modified RNAs followed by cDNA library preparation 
and high throughput NGS sequencing before occurrence and consensus motif (RRACU) of global m6A modifications 
are analyzed. (B) m1A‐ID‐seq workflow: RNA immunoprecipitation is carried out using anti‐m1A antibody to enrich 
m1A‐modified RNAs, which are then subjected to either the demethylase (−) treatment or the demethylase (+). Reverse 
transcription is stopped at m1A site in demethylase (−) group while extended in the demethylase (+) group. After NGS, 
m1A site can be identified by comparing the data of the demethylase (−) group to those of the demethylase (+) group.
Method Modification Strategies
m6A‐seq [26], MeRIP‐seq [36],  
m6A‐LAICIC‐seq [37]
m6A, m6Am Methyl‐RNA immunoprecipitation and UV cross‐linking
m1A‐ID‐seq [39] m1A Methyl‐RNA immunoprecipitation and the inherent ability of 
m1A to stall reverse transcription
Bisulfite sequencing [40] m5C Chemical conversion of modified nucleotides
ICE‐seq [42] A‐to‐I editing Cyanoethylation of RNA combined with reverse transcription
Pseudo‐seq [16], Ѱ‐seq [17] ѱ Chemical modification to terminate reverse transcription in 
the pseudouridylated site
NAD captureSeq [43] NAD Chemoenzymatic capture
Table 1. NGS‐based methods to profile transcriptome‐wide RNA modifications.
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immunoprecipitation and the m1A residue to cause truncated reverse transcription products, 
has been applied successfully for the transcriptome‐wide characterizations of m1A [39].
Chemical‐based methods rely on the misincorporation of nucleotide or nucleotide conver-
sion to truncate or stop RNA products during reverse transcription. RNA bisulfite conver-
sion followed by high‐throughput sequencing (BS‐seq, Figure 2A) is a chemical conversion 
method based on converting unmodified cytosine residues to uracil and keeping m5C 
residues unchanged by bisulfite treatment. BS‐seq is the only method currently available 
for the  detection of site‐specific endogenous m5C [40, 41]. Inosine chemical erasing (ICE) 
uses nucleotide switching to detect A‐to‐I modifications [42]. Inosine ribonucleotides are 
Figure 2. Chemical‐based strategies to detect RNA modification. (A) BS‐seq: Bisulfite selectively converts cytosine, not 
m5C, into uracil, subsequent to reverse transcription and RNA‐seq processes. After comparison with reference genome 
or control, m5C residues are identified as cytosine, whereas unmethylated cytosine as thymine. (B) ICE‐seq: The 
acrylonitrile can cyanoethylate inosine into N1‐cyanoethylinosine (ce1I). Reverse transcription will transcript inosine 
into cytidine but arrest at the ce1I site after the CE treatment. cDNA library, sequencing, reads mapping, and analysis 
will detect A‐to‐I sites. (C) Ѱ‐seq: The reagent CMC followed by incubation at alkaline pH leads to hydrolysis of U‐
CMC adducts, which are less stable than Ѱ‐CMC. Reverse transcription in Ѱ‐CMC sample will stop at Ѱ site. Following 
RNA‐seq and reads mapping will detect Ѱ sites with increased transcript termination in the CMC‐treated sample. (D) 
NAD captureSeq: ADPRC enzyme catalyzes a transglycosylation reaction of NAD with pentynol, which are bound by 
CuAAC with biotin azide. The RNA with NAD is captured by streptavidin beads before being readied for cDNA library 
preparation and sequenced for identifying NAD‐capped RNAs.
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cyanoethylated with acrylonitrile to form N1‐cyanoethylinosine (ce1I). Subsequently, the 
Watson‐Crick base pairing of I with C is inhibited by the newly formed N1‐cyanoethyl 
group of ce1I. Thus, cyanoethylation of I blocks cDNA synthesis by preventing extension 
of the cDNA that bears a cytosine (C) corresponding to the editing site during reverse 
transcription. However, I will be replaced by guanosine (G) [42] (Figure 2B). To detect 
RNA pseudouridylation, several groups developed Pseudo‐seq (Ѱ‐seq). RNA is treated 
with N
3
‐[N‐cyclohexyl‐Nʹ‐β‐(4‐methylmorpholinium) ethylcarbodiimide‐Ѱ (N
3
‐CMC‐Ѱ)], 
which binds covalently to U, G, and Ѱ residues and then exposed to alkaline pH to reduce 
stable U‐CMC and G‐CMC adducts. Reverse transcription will pause at the remaining 
intact Ѱ‐CMC sites, allowing for the mapping of Ѱ‐modifications [16, 17] (Figure 2C). 
Comparison of mapping reads from CMC‐treated samples versus non‐treated controls, 
Ѱ will be detected as the sites with an increased proportion of reads supporting reverse 
transcription termination. NAD captureSeq (Figure 2D) requires the chemo‐enzymatic 
modification of NAD which is capping the 5ʹ end of RNA. The first step, the transglyco-
sylation of NAD, is catalyzed by ADP‐ribosyl cyclase (ADPRC) from Aplysia californica in 
the presence of an alkynyl alcohol. In the second step, the modified NAD is biotinylated 
by a copper‐catalyzed azide‐alkyne cycloaddition. Thirdly, the biotin‐linked RNA is cap-
tured on streptavidin beads and processed further for cDNA library preparation and NGS. 
The NAD‐biotin‐captured sequences are then identified by comparison with the control 
samples which were not subjected to the first step of chemo‐enzymatic biotinylation [43].
4. Physiological functions of RNA modifications
Although we do not have full knowledge on the effects of RNA modification on physiologi-
cal function, there is increasing evidence that they play critical roles in the regulation of gene 
expression, cellular functions, and development. Disruptions of RNA modification mecha-
nisms have also been associated with disease. We present here a few examples, which dem-
onstrate the importance of RNA modification on physiological function.
As stated earlier, m6A modifications are commonly found throughout eukaryotes, as dem-
onstrated by multiple m6A‐seq studies. Human m6A‐seq analyses revealed 12,769 putative 
m6A sites within 6990 and 250 protein‐coding and non‐coding transcripts, respectively 
[26], whereas, in mice, 4513 m6A peaks were identified in 3376 and 66 protein‐coding and 
non‐coding transcripts, respectively [26]. The m6A consensus motif, RRACU, was iden-
tified with a median distance from m6A peaks of 24 nucleotides [26]. Interestingly, the 
majority of m6A sites were conserved between both mouse and human transcriptomes and 
enriched further within long internal exons and around stop codons, suggesting strong 
evolutionary selection [26, 36]. m6A‐LAIC‐seq showed that methylated transcripts utilized 
proximal alternative polyadenylation (APA) sites, which resulted in shorter 3′ untrans-
lated regions, whereas non‐methylated transcripts tended to use distal APA sites [37]. This 
observation correlated with the finding that m6A‐modified transcripts had both signifi-
cantly shorter RNA half lives and slightly lower translational efficiencies than unmarked 
transcripts [44].
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In vitro and in vivo genetic depletion of the m6A writer, Mettl3, in both mouse and human, 
led to the absence of m6A modification within Nanog mRNA which encodes a pluripotency 
factor. The absence of m6A marks extended Nanog expression throughout differentiation 
and inhibited embryonic stem cell exit from self‐renewal towards lineage differentiation [44]. 
m6A‐seq in mouse naïve embryonic stem cells (ESCs), 11‐day‐old embryoid bodies (EBs), and 
mouse embryonic fibroblasts (MEFs) revealed m6A marks in naïve pluripotency‐promoting 
genes reduced mRNA stability of key pluripotency‐promoting transcripts and facilitated dif-
ferentiation [45]. These findings suggest that m6A modification provides the flexibility of the 
stem cell transcriptome required to differentiate into different lineages [44]. NANOG is also 
important in both the maintenance and specification of cancer stem cells which can metas-
tasize and form primary tumors. The exposure of breast cancer cells to hypoxia induced 
the expression of the eraser ALKBH5 which resulted in m6A demethylation in the 3ʹ UTR of 
NANOG mRNA and the increased half life of NANOG mRNA, thereby promoting the breast 
cancer stem cell (BCSC) phenotype [46]. The m6A reader YTHDF2 protects the 5′ UTR of 
stress‐induced transcripts from demethylation. Cap‐independent translation initiation was 
enhanced by 5′ UTR methylation [47]. m6A modification is critical for the regulation of HIV‐1 
replication and HIV‐1ʹs effect on the host immune system [48]. HIV‐1 viral infection induced 
m6A modification in both host and viral mRNAs. HIV‐1 coding, non‐coding, and splicing 
regulatory regions contained a total of 14 m6A methylation peaks. In addition, methylation of 
two highly conserved m6A target sites in the HIV‐1 rev response element (RRE) stem loop II 
region enriched the binding of the HIV‐1 rev protein to the RRE in vivo and enhanced nuclear 
export of HIV‐1 RNA [48]. The long non‐coding RNA X‐inactive specific transcript (XIST) 
regulates transcriptional silencing of genes on the X chromosome. XIST is heavily modified 
with at least 78 m6A sites. Knockdown of METTL3 leads to decreased XIST m6A marks and 
impairs XIST‐mediated gene silencing [49].
The tRNA T‐loop at position 58 commonly contains a m1A modification [50], along with posi-
tion 9 of metazoan mitochondrial tRNAs [51] and eukaryotic rRNAs [52]. Initiator tRNAMet 
contains fully modified m1A 58 which stabilizes its tertiary structure. Hypomodification of 
tRNA m1A 58 affects the association with polysomes and the subsequent efficiency of transla-
tion [53, 54]. m1A modifications in tRNA function in response to environmental stress [55], 
whereas m1A‐modified rRNA regulates ribosome biogenesis [52]. m1A‐ID‐seq demonstrated 
that m1A methylation regulated the dynamic response to stimuli and identified 901 m1A 
peaks enriched within the 5ʹ UTR near the start codons of 600 distinct protein‐coding and 
non‐coding RNAs [39].
m5C sites have been detected in several eukaryotic tRNA, Rrna, and mRNA. m5C marks sta-
bilize the secondary structure of tRNA, alter aminoacylation and codon recognition [56], and 
regulate translational fidelity [57]. A low level of internal m5C was found in mRNA cap struc-
tures in mammalian‐ and virus‐infected mammalian cells [58, 59]. BS‐seq identified 10,275 
sites in protein‐coding and non‐coding RNAs [41]. m5C marks in mRNAs were enriched near 
argonaute‐binding sites within the 3ʹ UTR [41].
A‐to‐I editing sites are distributed through human mRNA, including exons, introns. and 5ʹ 
and 3ʹ UTRs [60]. Alu repeat elements contain the highest frequency of A‐to‐I editing sites 
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among the untranslated regions of the genome [61]. Intronic editing mediated by ADAR1 
contributes to the maintenance of mature mRNA by protecting it against unfavorable pro-
cessing of the Alu sequence and by degradation of aberrant transcripts by nonsense‐medi-
ated decay (NMD) [42]. A‐to‐I RNA editing is diminished in brain tissue from patients with 
Alzheimerʹs disease relative to controls [62]. The reduction occurs predominantly in the hip-
pocampus and to a lesser extent in the temporal and frontal lobes. These alterations result 
in decreased levels of protein recoding, the process of changing the amino acid sequence by 
A‐to‐I editing, in Alzheimerʹs disease [62]. The APOBEC3 family of cytidine deaminases has 
been associated with mutations in cancer genomes in several types of cancer. Accumulated 
data linking mutations in oncogenes and tumor suppressor genes with APOBEC3B activity 
are providing evidence that cytidine deaminase‐induced mutagenesis is activated in tumori-
genesis, thus providing novel therapeutic targets [63].
Pseudo‐seq revealed that mRNA Ψ marks mRNA are regulated in response to stimuli, such 
as serum starvation in human cells and nutrient deprivation in yeast. The observations indi-
cate that Ψ triggers a rapid regulatory mechanism to rewire the genetic code through induc-
ible mRNA [16]. Pseudouridylation of rRNA and telomerase RNA component (TERC) were 
also found to be reduced in dyskeratosis congenita patients [17]. Furthermore, missense 
mutations in pseudouridine synthase 1 (PUS1) may lead to deficient pseudouridylation 
of mitochondrial tRNAs in mitochondrial myopathy and sideroblastic anemia (MLASA) 
patients [64].
NAD captureSeq identified NAD as a 5ʹ RNA cap in a subset of regulatory RNAs in bacteria 
[43] and subsequently proposed that this type of capping may be common across all of life [65]. 
It is safe to predict that investigation of the roles and mechanisms of 5ʹ NAD caps in eukary-
otes will draw increasing attention in the biomedical field. This is due to mainly two reasons. 
First, the chemical modification of the 5ʹ end of RNA is critical for RNA processing, local-
ization, stability, translational efficiency, and epitranscriptomic regulation of gene expression 
[66]. Second, NAD is both a co‐substrate for enzymes, such as the sirtuins and poly(adenosine 
diphosphate‐ribose) polymerases, and a critical electron‐carrying coenzyme for enzymes that 
catalyze oxidation‐reduction reactions. NAD is involved in nearly all physiological processes. 
For example, cellular NAD+ levels are modulated during aging, and the use and production 
of NAD+ usage has been associated with prolonged health and life spans [67]. Regulation of 
NAD‐mediated RNA capping and hence gene expression will undoubtedly enrich our under-
standing of NADʹs expanding roles in normal physiology and disease pathogenesis.
5. Perspective
Although rapid advances have been made in the past few years in epitranscriptomics, 
more work is needed in this field. To date, more than 140 different RNA modifications 
have been identified. However, there are only a few reliable high‐throughput techniques 
available to determine the global occurrence of a particular RNA modification. Thus, 
there is a need for the development of more high‐throughput techniques to characterize 
the full spectra of RNA modifications. It is also important to pursue the comprehensive 
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identification and  characterization of the enzymes responsible for RNA modification since 
several of these enzymes have been shown to play important roles in development and 
disease. It is essential to decipher all functions and disease involvements of all RNA mod-
ifications. Development of additional technologies to alter RNA modifications, includ-
ing the engineering of RNA‐modifying enzymes with modified substrate specificity and 
activity via the CRISPR‐Cas 9 system, will open the door to new types of detection and 
analysis pipelines. With further technological development, we will be able to elucidate 
the sequence‐specific signatures in RNA that direct modifications and then better relate 
these RNA marks to their corresponding biological functions. Finally, the advancement 
of current approaches, coupled with new technologies, will allow for the development of 
new therapies and therapeutic targets for human diseases associated with deficient RNA 
modification.
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